This is a rare type of cancer that starts in the placenta. It's made up mostly of a specific type of cell called cytotrophoblasts. Because it doesn't usually make much of the hormone hCG, it can grow quite large before doctors notice it.
Every report comes from a Lived member, sent anonymously.
Have you had Hysterectomy for Placental Site Trophoblastic Tumor?
Placental site trophoblastic tumor (PSTT) is a very rare cancer that develops from pregnancy tissue. During pregnancy, specialized cells called trophoblasts anchor the placenta into the wall of the uterus. In PSTT, some of these cells remain after the pregnancy ends and grow into a tumor at the spot where the placenta was attached, spreading into the muscle of the uterus and its blood vessels. PSTT grows slowly, so symptoms often appear months or even years after a pregnancy. The most common sign is irregular vaginal bleeding; some people instead stop having periods, and a few have no symptoms. In some people it spreads beyond the uterus, most often to the lungs, pelvis or lymph nodes. PSTT belongs to a group called gestational trophoblastic disease, which also includes molar pregnancy and choriocarcinoma. It behaves differently from those relatives: it makes less of the pregnancy hormone, grows more slowly and responds less well to chemotherapy. Those differences shape how it is diagnosed and treated.
PSTT always follows a pregnancy, because it grows from cells that came from the placenta. It most often appears after a full-term birth, but it can follow other pregnancies, including a molar pregnancy (an abnormal pregnancy in which the placenta grows as a mass of cysts instead of supporting a fetus). Most people diagnosed are in their late 20s or early 30s. Researchers do not know why these cells persist and turn into a tumor in a very small number of people, and no lifestyle factor or pregnancy event has been shown to cause it. Older age at pregnancy and a previous molar pregnancy have been linked to a higher chance of trophoblastic tumors in general, but PSTT is so uncommon, roughly 1 in 100,000 pregnancies, that nobody is routinely screened for it.
Evaluation usually begins with abnormal bleeding or missed periods after a pregnancy has ended. A doctor orders a blood test for human chorionic gonadotropin (hCG), the hormone that pregnancy tests detect, along with a pelvic ultrasound. In PSTT, hCG is often only mildly or moderately raised, much lower than in choriocarcinoma, and the level does not reliably show how large the tumor is. A modest hCG result therefore does not rule PSTT out. The diagnosis is confirmed by examining tumor tissue under a microscope, sometimes with special stains that identify the cell type. Tissue may come from a scraping of the uterine lining, but this can miss the tumor when it sits deep in the muscle, so some people are diagnosed only after hysterectomy. Pathologists also need to distinguish PSTT from related conditions, including choriocarcinoma, epithelioid trophoblastic tumor (an even rarer cousin) and harmless leftover placental-site tissue. Once PSTT is confirmed, scans such as magnetic resonance imaging (MRI) of the pelvis and computed tomography (CT) of the chest and abdomen show whether it has spread. Doctors then assign a stage from I (confined to the uterus) to IV (spread to distant organs). Unlike other trophoblastic cancers, PSTT is not graded with the usual hCG-based risk score; instead, the time since the pregnancy that led to the tumor is recorded alongside the stage.
Because PSTT is rare, it is best managed by a gynecologic oncologist (a surgeon who specializes in cancers of the female reproductive organs) at a center experienced with trophoblastic disease. Treatment depends mainly on stage and on whether the person wants a future pregnancy. When the tumor is confined to the uterus, removing the uterus (hysterectomy) is the main treatment. Surgery comes first because PSTT, unlike most trophoblastic cancers, often does not respond fully to chemotherapy. In one long-term series, about 9 in 10 people treated this way were alive 10 years later. Chemotherapy may be added after surgery when the tumor has features linked to a higher chance of return, such as deep growth into the uterine wall or a pregnancy more than four years earlier. When the tumor has spread, treatment usually combines several chemotherapy drugs given together, often with surgery to remove the uterus and any tumor that can be reached, such as spots in the lungs. These regimens are intensive and need close monitoring by the treating team. No regimen has been proven better than another, so the choice rests on specialist experience. For people who want to keep the ability to become pregnant, a few centers have removed only the tumor and preserved the uterus. This has been reported only in small numbers of carefully selected people with early, localized disease, and it requires detailed counseling about the uncertain safety of leaving the uterus in place. Immunotherapy that blocks PD-1, a signal that helps tumors avoid the immune system, such as pembrolizumab (Keytruda), has produced responses in some people whose PSTT resisted chemotherapy. Evidence so far comes from case reports, so it is usually considered in specialist care or a clinical trial.
Outlook depends heavily on how far the tumor has spread and how long ago the pregnancy was. When PSTT is found while still confined to the uterus and is treated with surgery, most people are cured. The two features most clearly linked to a poorer outcome are spread to distant organs and diagnosis 48 months (four years) or more after the pregnancy that led to the tumor. Overall, reported death rates across studies range from about 6 to 27 percent, reflecting how differently these groups fare. Losing the uterus ends the ability to carry a pregnancy, which can be a significant loss, especially for younger people, and counseling or support may help. After treatment, follow-up includes regular hCG blood tests, and sometimes scans, to check that the tumor has not returned. Because PSTT makes relatively little hCG, a normal result is reassuring but not the whole picture, which is why imaging may be added. How often and for how long testing continues is set by the treating center.
Arrange an appointment if you have vaginal bleeding that is not a normal period, bleeding that continues longer than expected after giving birth, or periods that stop without a new pregnancy, in the months or years after any pregnancy. These symptoms usually have other causes, but they deserve evaluation. If you have been treated for PSTT, contact your care team promptly if bleeding returns or a follow-up hCG test is rising, since either can signal that the tumor has come back.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Placental Site Trophoblastic Tumor is like, what's helped you, or ask the community a question.